Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus

Pharmacogenetics and Genomics

Volumn 23, Issue 12, 2013, Pages 649-657

  Elens, Laure ^a,c   Sombogaard, Ferdi ^a,b   Hesselink, Dennis A ^c   Van Schaik, Ron H N ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Kidney transplantation; New onset diabetes after transplantation; P450 oxidoreductase; Peroxisome proliferator activated receptor ; Pharmacogenetics; Single nucleotide polymorphism; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLELE; ARTICLE; BODY WEIGHT; DIABETES MELLITUS; DRUG DOSE REDUCTION; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW ONSET DIABETES AFTER TRANSPLANTATION; POR GENE; PPARALPHA GENE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; AGED; DIABETES MELLITUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPING TECHNIQUES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; PROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; YOUNG ADULT;

EID: 84895074203     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000001     Document Type: Article

References (53)

1. Balla A, Chobanian M. New-onset diabetes after transplantation: A review of recent literature. Curr Opin Organ Transplant 2009; 14:375-379.
2. Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y. Patient survival and cardiovascular risk after kidney transplantation: The challenge of diabetes. Am J Transplant 2008; 8:593-599.
3. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney ransplantation. Kidney Int 2005; 67:2415-2421.
4. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive summary: Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105:2231-2239.
5. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-185.
6. Young JB, Neumayer HH, Gordon RD. Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk. Kidney Int Suppl 2010; 118:S1-S7.
7. Yates CJ, Fourlanos S, Hjelmesaeth J, Colman PG, Cohney SJ. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant 2012; 12:820-828.
8. Webster AC,Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331:810.
9. Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, et al. IL-6 promoter polymorphism - 174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 2006; 17:2333-2340.
10. Chen Y, Sampaio MS, Yang JW, Min D, Hutchinson IV. Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 2012; 93:325-330.
11. Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi JM, Rerolle JP, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 2009; 20:2459-2467.
12. Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW, et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008; 57:1043-1047.
13. Tavira B, Coto E, Torres A, Diaz-Corte C, Diaz-Molina B, Ortega F, et al. Association between a common KCNJ11 polymorphism (rs5219) and newonset posttransplant diabetes in patients treated with tacrolimus. Mol Genet Metab 2012; 105:525-527.
14. Veldt BJ, Duarte-Rojo A, Thompson AJ,Watt KD, Heimbach JK, Tillmann HL, et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant 2012; 12:737-744.
15. Holmkvist J, Almgren P, Lyssenko V, Lindgren CM, Eriksson KF, Isomaa B, et al. Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes 2008; 57:1738-1744.
16. Willer CJ, Bonnycastle LL, Conneely KN, Duren WL, Jackson AU, Scott LJ, et al. Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes 2007; 56:256-264.
17. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116:571-580.
18. Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M Group S-NS. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptoralpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: The STOP-NIDDM trial. Diabetes 2007; 56:1181-1186.
19. Bosse Y, Despres JP, Bouchard C, Perusse L, Vohl MC. The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity. Obes Res 2003; 11:809-816.
20. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med (Berl) 2001; 79:198-204.
21. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, et al. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 2000; 43:673-680.
22. Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M, Kotzka J, Berthold HK, et al. Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am Heart J 2004; 147:1117-1124.
23. Robitaille J, Brouillette C, Houde A, Lemieux S, Perusse L, Tchernof A, et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004; 49:482-489.
24. Shin MJ, Kanaya AM, Krauss RM. Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 2008; 198:313-319.
25. Silbernagel G, Stefan N, Hoffmann MM, Machicao-Arano F, Machann J, Schick F, et al. The L162V polymorphism of the peroxisome proliferators activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition. Exp Clin Endocrinol Diabetes 2009; 117:113-118.
26. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ, et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 2005; 135:397-403.
27. Uthurralt J, Gordish-Dressman H, Bradbury M, Tesi-Rocha C, Devaney J, Harmon B, et al. PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet 2007; 8:55.
28. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, et al. Molecular scanning of the human PPARa gene: Association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41:945-952.
29. Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M, et al. PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther 2012; 91:1044-1052.
30. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 2001; 276:29163-29170.
31. Guengerich FP. Cytochrome P450: What have we learned and what are the future issues? Drug Metab Rev 2004; 36:159-197.
32. Gotoh O. Evolution of cytochrome p450 genes from the viewpoint of genome informatics. Biol Pharm Bull 2012; 35:812-817.
33. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002; 277:6536-6541.
34. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003; 278:13480-13486.
35. Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 2010; 20:611-618.
36. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008; 105:1733-1738.
37. Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, et al. Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 2011; 336:174-179.
38. Sombogaard F, Peeters AM, Baan CC, Mathot RA, Quaedackers ME, Vulto AG, et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetiltreated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 2009; 31:549-556.
39. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics 2009; 19:626-634.
40. Hesse CJ, Baan CC, Balk AH, Metselaar HJ, Weimar W, van Gelder T. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. Transplant Proc 2002; 34:2988-2990.
41. Boyles AL, Scott WK, Martin ER, Schmidt S, Li YJ, Ashley-Koch A, et al. Linkage disequilibrium inflates type I error rates in multipoint linkage analysis when parental genotypes are missing. Hum Hered 2005; 59:220-227.
42. Tordjman K, Bernal-Mizrachi C, Zemany L,Weng S, Feng C, Zhang F, et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 2001; 107:1025-1034.
43. Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, et al. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 2006; 55:1605-1613.
44. Ueshiba H, Shimizu Y, Hiroi N, Yakushiji F, Shimojo M, Tsuboi K, et al. Decreased steroidogenic enzyme 17,20-lyase and increased 17-hydroxylase activities in type 2 diabetes mellitus. Eur J Endocrinol 2002; 146:375-380.
45. Bates GW Jr, Egerman RS, Umstot ES, Buster JE, Casson PR. Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann N Y Acad Sci 1995; 774:291-293.
46. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011; 12:1281-1291.
47. Diaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Transplant Proc 2012; 44:2635-2638.
48. Tavira B, Coto E, Diaz-Corte C, Ortega F, Arias M, Torres A, et al. Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med 2011; 49:825-833.
49. Hamer RA, Chow CL, Ong AC, McKaneWS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83:36-40.
50. Ducloux D, Motte G, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant 1999; 14:1244-1246.
51. Vareesangthip K, Tong P,Wilkinson R, Thomas TH. Insulin resistance in adult polycystic kidney disease. Kidney Int 1997; 52:503-508.
52. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564-577.
53. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165:710-718.